Sonoma Pharmaceuticals (SNOA) Retained Earnings (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Retained Earnings of -$201.0 million for Q1 2026, down 4492.8% year-over-year from $4.6 million in Q1 2025, and little changed quarter-over-quarter from -$200.4 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Retained Earnings (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Retained Earnings history runs 16 years deep, the most recent figure standing at -$201.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 4492.8% year-over-year to -$201.0 million; the TTM figure through Mar 2026 stood at -$201.0 million (down 4492.8% YoY), while the FY2026 annual figure was -$201.0 million, down 4492.8% from the prior year.
- Retained Earnings for Q1 2026 stood at -$201.0 million, roughly flat from -$200.4 million in the prior quarter.
- The five-year high for Retained Earnings was -$2.8 million in Q4 2023, with the low at -$201.0 million in Q1 2026.
- The 5-year median for Retained Earnings is -$4.6 million (2024), against an average of -$94.3 million.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings surged 98.32% in 2023, then sank 5586.04% in 2024.
- Sonoma Pharmaceuticals' Retained Earnings stood at -$4.2 million in 2022, then surged by 32.4% to -$2.8 million in 2023, then slumped by 61.32% to -$4.6 million in 2024, then plunged by 4300.53% to -$200.4 million in 2025, then slipped by 0.29% to -$201.0 million in 2026.
- Business Quant data shows SNOA's Retained Earnings at -$201.0 million in Q1 2026, -$200.4 million in Q4 2025, and -$199.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 3.75 Bn |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | -201.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -201.31 Mn |
| Mar 31, 2026 | -200.98 Mn |
| Dec 31, 2025 | -200.40 Mn |
| Sep 30, 2025 | -199.58 Mn |
| Jun 30, 2025 | -199.05 Mn |
| Mar 31, 2025 | -4.38 Mn |
| Dec 31, 2024 | -4.55 Mn |
| Sep 30, 2024 | -4.20 Mn |
| Jun 30, 2024 | -195.49 Mn |
| Mar 31, 2024 | -194.35 Mn |
| Dec 31, 2023 | -2.82 Mn |
| Sep 30, 2023 | -3.12 Mn |
| Jun 30, 2023 | -190.93 Mn |
| Mar 31, 2023 | -3.42 Mn |
| Dec 31, 2022 | -4.18 Mn |
| Sep 30, 2022 | -186.27 Mn |
| Jun 30, 2022 | -4.38 Mn |
| Mar 31, 2022 | -4.31 Mn |
| Dec 31, 2021 | -181.42 Mn |
| Sep 30, 2021 | -180.48 Mn |